Test Short

Intervention · Demographic · Gender

Bleeding Risk, Sex Differences, and the Future of Structural Heart

Ankur Kalra

Watch time: 53m 46s

Imaging & Diagnostics · Intervention · Structural Intervention

Evolution of 3D ICE Imaging in TTVR: Introduction

Nadira Hamid

Watch time: 2m 39s

Imaging & Diagnostics · Intervention · Structural Intervention

Case Presentation of 3D ICE Only and TTVR

Pradeep Yadav

Watch time: 18m 8s

Imaging & Diagnostics · Intervention · Structural Intervention

Key Concepts of 3D ICE in TTVR Imaging

Lynne Brown

Watch time: 14m 49s

Imaging & Diagnostics · Intervention · Structural Intervention

Evolution of 3D ICE Imaging in TTVR: Panel Discussion

Nadira Hamid, Pradeep Yadav, Lynne Brown

Watch time: 13m 8s

Intervention · Coronary Interventions · Coronary Physiology +1

Coronary Reactivity Testing for Non‑Obstructive CAD: Case Overview

Watch time: 2m 47s

Imaging & Diagnostics · Intervention · Coronary Interventions +2

Indication and Cath Lab setup

Watch time: 4m 19s

Imaging & Diagnostics · Intervention · Coronary Interventions +2

Adenosine physiology: CFR and IMR

Watch time: 2m 17s

Imaging & Diagnostics · Intervention · Coronary Interventions +2

ACh Protocol and Spasm Testing

Watch time: 3m 51s

Imaging & Diagnostics · Intervention · Coronary Interventions +2

Cath Lab Guide: Final Diagnosis and Take Home Points

Watch time: 3m 7s

Intervention · Structural Intervention

TriClip Tricuspid TEER: System Insertion and Trajectory Optimisation

Watch time: 6m 4s

Intervention · Structural Intervention

TriClip Tricuspid TEER: The Second Clip and Managing Lead Interference

Watch time: 11m 45s

Intervention · Structural Intervention

TriClip Tricuspid TEER: Post-Procedure, Efficiency and Outcomes

Watch time: 3m 45s

Electrophysiology & Arrhythmia · Heart Failure · Heart Failure Diagnosis and Imaging +1

AI-ECG Enhances Heart Failure Risk Prediction

Heart Failure · Chronic Heart Failure Management · Cardiomyopathies +1

Aficamten Superior to Metoprolol in oHCM: MAPLE-HCM

Intervention · Coronary Interventions · STEMI

iMODERN: No Benefit for Immediate Nonculprit-Lesion PCI

Stroke · Cardiovascular Kidney Metabolic · Demographic +3

Higher ARR Linked to AF and Stroke Risk in Older Adults

Cardiovascular Kidney Metabolic

Semaglutide May Aid Vascular Repair in High-Risk Patients

MI/ACS · Stroke · Cardiovascular Kidney Metabolic +2

Aldosteronism Linked to AF and Stroke Risk in Older Adults

Intervention · Structural Intervention · Demographic +1

TEER Linked to Better Outcomes in AFMR Patients

Intervention · Structural Intervention · Stroke +5

DEDICATE: TAVI vs SAVR Outcomes by Sex in Aortic Stenosis

Electrophysiology & Arrhythmia · Pacing, Defibrillators & Cardiac Resynchronisation Therapy · Heart Failure

LBBP Superior to BiVP for HF Outcomes in HeartSync-LBBP

Imaging & Diagnostics · Intervention · Structural Intervention

Spotting a Suitable Valve for TEER: The Foundations of MR/TR Imaging

Imaging & Diagnostics · Intervention · Structural Intervention

Mastering Mitral Anatomy: Precision Leaflet Grasping for Every Anatomy

Imaging & Diagnostics · Intervention · Structural Intervention

Nail It with Nadira: Evolution of 3D ICE Imaging in TTVR

CV Disease in Special Populations · Cardio-oncology

Virtual Abstract Presentations from GC-OS 2025

Joe Carver, Dan Lenihan, Pouya Joolharzadeh

Vascular Disease and Surgery

AVC 2026: Deep and Pelvic Venous Disorders – Case-Based Insights

Imaging & Diagnostics · CT/MRI · Intervention +2

Transforming LAAO Planning With 3D Simulations: Clinical Evidence, Accuracy and Real-World Impact

CV Disease in Special Populations · Cardio-oncology

Cardiac Masses in Cardio-Oncology: Cardiac Masses at the Crossroads of Oncology and Cardiology

Joe Carver, Dan Lenihan, Pouya Joolharzadeh

CV Disease in Special Populations · Cardio-oncology

Prostate Cancer: The Role of Androgen Deprivation and Cardiovascular Health

Joe Carver, Dan Lenihan, Pouya Joolharzadeh

Heart Failure · Cardiomyopathies and Cardiac Amyloidosis · Cardiac Amyloidosis +2

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Evidence, Experience and Evolving Approaches

Prevention & Chronic Conditions · Hypertension · Cardiovascular Kidney Metabolic +10

e-SPACE Cardio-Renal-Metabolic 2026 – Day One

Prevention & Chronic Conditions · Hypertension · Cardiovascular Kidney Metabolic +10

e-SPACE Cardio-Renal-Metabolic 2026 – Day Two

Intervention · Structural Intervention

Tricuspid TEER — Anatomy‑Driven Planning and Execution

Cardiovascular Kidney Metabolic · Cardiovascular Surgery · Electrophysiology & Arrhythmia +1

Cardiometabolic Disease in Asia-Pacific Populations: Semaglutide as the Standard of Care in Obesity

CV Disease in Special Populations · Cardio-oncology

A Novel Risk Score for ICI Myocarditis

Joe Carver, Dan Lenihan, Pouya Joolharzadeh

Electrophysiology & Arrhythmia

#LetsDuoIt: Meet TactiFlex™ Duo — Powering the Next Evolution of PFA

Cardiovascular Kidney Metabolic · Cardiovascular Co-Morbidities · Obesity +1

GLP-1 RAs and Cardiovascular Care: A New Era of Risk Reduction

MI/ACS · Prevention & Chronic Conditions · Cardiovascular Kidney Metabolic +3

Targeting Residual Inflammatory Risk

Smeeta Sinha

Intervention · Coronary Interventions

Laser Focus: Clinical Insights From the Front Line

Carlo Tumscitz, Piotr Wacinski, Alfonso Jurado-Román, Mohsen Mohandes, Javier Suárez de Lezo

MI/ACS · Prevention & Chronic Conditions · Cardiovascular Kidney Metabolic +3

Targeting Residual Inflammatory Risk: The Microlearning Series

Smeeta Sinha

Electrophysiology & Arrhythmia · Atrial Arrhythmias · Atrial Fibrillation +3

AF Symposium 2026 Late-Breaking Science Collection

Atul Verma

Cardiovascular Kidney Metabolic · Prevention & Chronic Conditions · Atherosclerosis and Hyperlipidemia

NHD 2026

Kausik Ray, Daniel Gaudet, Lale Tokgözoğlu, Nick Nurmohamed

Cardiovascular Risk Reduction – A New Paradigm With GLP-1 RAs

GLP-1 RAs and Cardiovascular Care: A New Era of Risk Reduction

Watch time: 14m 41s

GLP-1 RAs and Cardiovascular Protection – Rethinking Their Role

GLP-1 RAs and Cardiovascular Care: A New Era of Risk Reduction

Watch time: 15m 20s

Welcome and Introduction

Targeting Residual Inflammatory Risk: The Future of Cardiovascular Prevention

Smeeta Sinha

Watch time: 2m 47s

Evidence That Matters: ROLLERCOASTR Trial Highlights

Laser Focus: Clinical Insights From the Front Line

Alfonso Jurado-Román

Watch time: 3m 19s

Understanding the Unmet Need: The Residual Risk Puzzle

Targeting Residual Inflammatory Risk: The Future of Cardiovascular Prevention

Watch time: 11m 29s

Measuring What Matters: Tools for Identification and Monitoring

Targeting Residual Inflammatory Risk: The Future of Cardiovascular Prevention

Watch time: 10m 37s

Targeting Inflammation: The Future of Therapy

Targeting Residual Inflammatory Risk: The Future of Cardiovascular Prevention

Watch time: 14m 56s

Integrating Inflammation Management into Practice: Real-world Strategies and Case Discussions

Targeting Residual Inflammatory Risk: The Future of Cardiovascular Prevention

Watch time: 6m 42s

Cardiovascular Risk Reduction – A New Paradigm With GLP-1 RAs

GLP-1 RAs and Cardiovascular Care: A New Era of Risk Reduction

GLP-1 RAs and Cardiovascular Protection – Rethinking Their Role

GLP-1 RAs and Cardiovascular Care: A New Era of Risk Reduction

Welcome and Introduction

Targeting Residual Inflammatory Risk: The Future of Cardiovascular Prevention

Evidence That Matters: ROLLERCOASTR Trial Highlights

Laser Focus: Clinical Insights From the Front Line

Clinical impact demo — Practice-Changing

Test sandbox card (safe to delete)

Clinical impact demo — High Impact

Test sandbox card (safe to delete)

Clinical impact demo — Important Signal

Test sandbox card (safe to delete)

Clinical impact demo — Emerging Innovation

Test sandbox card (safe to delete)

Clinical impact demo — Early Data

Test sandbox card (safe to delete)